immunotherapy

138 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati

Section: Hematology-OncologyFeb 19, 2026

Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial

The Phase 2 LARA trial demonstrates that combining pembrolizumab and lenvatinib yields a 40% objective response rate in recurrent gynaecological clear cell carcinoma, offering a potential new standard for this historically chemo-resistant a

immunotherapy

Latest news

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC

Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL